B. Metzler seel. Sohn & Co. Holding AG bought a brand new place in Insulet Co. (NASDAQ:PODD – Free Report) within the third quarter, in keeping with the corporate in its most up-to-date disclosure with the SEC. The fund bought 9,542 shares of the medical devices provider’s inventory, valued at roughly $2,221,000.
Different hedge funds additionally just lately purchased and offered shares of the corporate. Baillie Gifford & Co. raised its holdings in Insulet by 20.7% within the third quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical devices provider’s inventory value $529,669,000 after shopping for an extra 389,639 shares over the past quarter. Clearbridge Investments LLC raised its holdings in Insulet by 6.0% within the 2nd quarter. Clearbridge Investments LLC now owns 1,339,763 shares of the medical devices provider’s inventory value $270,364,000 after buying an extra 75,526 shares over the past quarter. American Century Firms Inc. lifted its place in Insulet by 18.7% within the 2nd quarter. American Century Firms Inc. now owns 885,669 shares of the medical devices provider’s inventory valued at $178,728,000 after buying an extra 139,246 shares within the final quarter. Marshall Wace LLP bought a brand new stake in Insulet through the 2nd quarter valued at $99,978,000. Lastly, Canada Pension Plan Funding Board elevated its holdings in shares of Insulet by 206.9% within the 1st quarter. Canada Pension Plan Funding Board now owns 429,591 shares of the medical devices provider’s inventory value $73,632,000 after buying an extra 289,591 shares within the final quarter.
Insulet Inventory Down 1.3 %
NASDAQ PODD opened at $262.99 on Friday. The inventory’s 50-day transferring common value is $240.74 and its 200-day transferring common value is $209.99. The corporate has a market capitalization of $18.45 billion, a P/E ratio of 45.03, a price-to-earnings-growth ratio of 4.01 and a beta of 1.22. The corporate has a fast ratio of two.80, a present ratio of three.68 and a debt-to-equity ratio of 1.21. Insulet Co. has a 52 week low of $160.19 and a 52 week excessive of $279.40.
Analyst Upgrades and Downgrades
Quite a few analysis analysts have just lately issued studies on PODD shares. Canaccord Genuity Group upped their value goal on Insulet from $236.00 to $269.00 and gave the corporate a “purchase” ranking in a report on Wednesday, September twenty fifth. Barclays upped their goal value on shares of Insulet from $220.00 to $234.00 and gave the corporate an “equal weight” ranking in a analysis notice on Monday, November eleventh. Piper Sandler lifted their value goal on shares of Insulet from $230.00 to $285.00 and gave the inventory an “chubby” ranking in a analysis notice on Tuesday, September seventeenth. Citigroup elevated their value goal on shares of Insulet from $250.00 to $275.00 and gave the corporate a “purchase” ranking in a analysis report on Tuesday, October 1st. Lastly, BTIG Analysis lifted their goal value on shares of Insulet from $260.00 to $270.00 and gave the inventory a “purchase” ranking in a analysis report on Friday, November eighth. Three analysts have rated the inventory with a maintain ranking and twelve have given a purchase ranking to the inventory. Based mostly on information from MarketBeat, the inventory presently has a consensus ranking of “Reasonable Purchase” and a consensus goal value of $253.27.
Get Our Newest Inventory Report on PODD
Insulet Firm Profile
Insulet Company develops, manufactures, and sells insulin supply programs for individuals with insulin-dependent diabetes. The corporate’s Omnipod platform contains the Omnipod 5 Automated Insulin Supply System (Omnipod 5) which features a proprietary AID algorithm embedded within the Pod that integrates with a third-party steady glucose monitor to acquire glucose values via wi-fi bluetooth communication; Omnipod DASH that incorporates a bluetooth enabled Pod that’s managed by a smartphone-like Private Diabetes Supervisor with a colour contact display screen consumer interface; and Omnipod GO, a standalone, wearable, insulin supply system that gives a set price of steady rapid-acting insulin for 72 hours.
Featured Tales
Obtain Information & Rankings for Insulet Each day – Enter your electronic mail tackle under to obtain a concise day by day abstract of the newest information and analysts’ rankings for Insulet and associated firms with MarketBeat.com’s FREE day by day electronic mail e-newsletter.
